MediWound Ltd.(MDWD)Earnings, Financials & Key Ratios
MDWD•NASDAQ
$17.27
$222M mkt cap·Price updated May 7, 2026
AboutMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.Show more
- Revenue$17M-16.1%
- EBITDA-$24M-31.7%
- Net Income-$24M+21.0%
- EPS (Diluted)-2.10+30.7%
- Gross Margin12.59%+42.9%
- EBITDA Margin-138.98%-57.0%
- Operating Margin-149.06%-55.5%
- Net Margin-140.8%+5.8%
- ROE-63.86%+33.7%
- ROIC-49.54%+6.3%
- Debt/Equity0.20-9.6%
- Interest Coverage-38.13-10.4%
MDWD Key Insights
MediWound Ltd. (MDWD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 14.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MDWD Price & Volume
MediWound Ltd. (MDWD) stock price & volume — 10-year historical chart
Loading chart...
MDWD Growth Metrics
MediWound Ltd. (MDWD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.65%
5 Years-4.87%
3 Years-13.82%
TTM-16.14%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.99%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM31.69%
Return on Capital
10 Years-35.83%
5 Years-44.21%
3 Years-39.31%
Last Year-47.03%
MDWD Recent Earnings
MediWound Ltd. (MDWD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
Mar 5, 2026EPS
$0.56
Est $0.65
+13.8%
Revenue
$2M
Est $4M
-55.5%
Q4 2025
Nov 20, 2025EPS
$0.24
Est $0.81
+70.4%
Revenue
$5M
Est $2M
+160.1%
Q3 2025
Aug 14, 2025EPS
$1.23
Est $0.55
-123.6%
Revenue
$6M
Est $7M
-13.0%
Q2 2025
May 21, 2025EPS
$0.07
Est $0.65
+89.2%
Revenue
$4M
Est $6M
-31.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.56vs $0.65+13.8% | $2Mvs $4M-55.5% |
| Q4 2025 | Nov 20, 2025 | $0.24vs $0.81+70.4% | $5Mvs $2M+160.1% |
| Q3 2025 | Aug 14, 2025 | $1.23vs $0.55-123.6% | $6Mvs $7M-13.0% |
| Q2 2025 | May 21, 2025 | $0.07vs $0.65+89.2% | $4Mvs $6M-31.4% |
Based on last 12 quarters of dataView full earnings history →
MDWD Peer Comparison
MediWound Ltd. (MDWD) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SLXN | 1.62M | 0.52 | -0.06 | -387.82% | 0.18 | |||
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 BLFS | 1.13B | 23.12 | -92.48 | 16.97% | -10.52% | -2.91% | 0.05 | |
 KROS | 433.26M | 11.64 | 5.06 | 67.75% | 35.65% | 14.25% | 0.06 | |
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 XTLB | 293.77K | 2.67 | -0.28 | -227.72% | -25.53% | 0.03 | ||
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 SYK | 112.69B | 294.25 | 35.03 | 11.16% | 12.92% | 15.04% | 0.66 |
Compare MDWD vs Peers
MediWound Ltd. (MDWD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDWD Income Statement
MediWound Ltd. (MDWD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.5M | 3.4M | 31.79M | 21.76M | 23.76M | 26.5M | 18.69M | 20.22M | 16.96M |
| Revenue Growth % | 60.21% | 36.26% | 834.7% | -31.54% | 9.19% | 11.5% | -29.48% | 8.22% | -16.14% |
| Cost of Goods Sold | 1.69M | 2.19M | 12.49M | 14.75M | 15.63M | 14.18M | 15.74M | 18.44M | 14.82M |
| COGS % of Revenue | 67.63% | 64.42% | 39.28% | 67.79% | 65.76% | 53.5% | 84.23% | 91.19% | 87.41% |
| Gross Profit | 808K▲ 0% | 1.21M▲ 49.8% | 19.3M▲ 1495.2% | 7.01M▼ 63.7% | 8.14M▲ 16.1% | 12.32M▲ 51.4% | 2.95M▼ 76.1% | 1.78M▼ 39.6% | 2.13M▲ 19.9% |
| Gross Margin % | 32.37% | 35.58% | 60.72% | 32.21% | 34.24% | 46.5% | 15.77% | 8.81% | 12.59% |
| Gross Profit Growth % | 213.48% | 49.75% | 1495.21% | -63.69% | 16.08% | 51.43% | -76.08% | -39.57% | 19.88% |
| Operating Expenses | 14.49M | 11.96M | 13.64M | 15.85M | 19.36M | 19.98M | 18.45M | 21.16M | 27.41M |
| OpEx % of Revenue | 580.73% | 351.54% | 42.9% | 72.83% | 81.46% | 75.41% | 98.73% | 104.66% | 161.65% |
| Selling, General & Admin | 9.07M | 7.93M | 9.01M | 8.5M | 9.45M | 10.37M | 11.38M | 12.91M | 13.93M |
| SG&A % of Revenue | 363.58% | 233.31% | 28.34% | 39.04% | 39.78% | 39.14% | 60.89% | 63.84% | 82.11% |
| Research & Development | 5.42M | 4.02M | 4.63M | 7.35M | 9.9M | 9.61M | 7.07M | 8.25M | 13.49M |
| R&D % of Revenue | 217.15% | 118.23% | 14.56% | 33.78% | 41.68% | 36.27% | 37.84% | 40.82% | 79.54% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -13.69M▲ 0% | -10.75M▲ 21.5% | 5.67M▲ 152.7% | -8.84M▼ 256.0% | -11.22M▼ 26.9% | -7.66M▲ 31.7% | -15.5M▼ 102.3% | -19.38M▼ 25.0% | -25.28M▼ 30.4% |
| Operating Margin % | -548.36% | -315.97% | 17.82% | -40.62% | -47.22% | -28.91% | -82.96% | -95.85% | -149.06% |
| Operating Income Growth % | 32.09% | 21.49% | 152.72% | -256.05% | -26.93% | 31.73% | -102.34% | -25.04% | -30.42% |
| EBITDA | -13.12M | -10.17M | 6.82M | -7.75M | -9.98M | -6.39M | -14.2M | -17.9M | -23.57M |
| EBITDA Margin % | -525.64% | -299% | 21.44% | -35.61% | -42.01% | -24.12% | -75.98% | -88.52% | -138.98% |
| EBITDA Growth % | 32.94% | 22.49% | 167.02% | -213.72% | -28.81% | 35.99% | -122.19% | -26.07% | -31.67% |
| D&A (Non-Cash Add-back) | 567K | 577K | 1.15M | 1.09M | 1.24M | 1.27M | 1.3M | 1.48M | 1.71M |
| EBIT | -14.53M | -5.67M | 2.27M | -9.08M | -13.36M | -19.36M | -6.2M | -29.6M | -25.28M |
| Net Interest Income | 349K | 412K | 227K | 97K | -156K | 108K | 2.01M | 1.49M | 1.2M |
| Interest Income | 349K | 412K | 434K | 297K | 11K | 270K | 2.34M | 2.05M | 1.86M |
| Interest Expense | 0 | 0 | 207K | 200K | 167K | 162K | 335K | 561K | 663K |
| Other Income/Expense | -846K | 5.08M | -3.6M | -436K | -2.3M | -11.86M | 8.97M | -10.78M | 1.57M |
| Pretax Income | -14.53M▲ 0% | -5.67M▲ 61.0% | 2.07M▲ 136.5% | -9.28M▼ 549.0% | -13.52M▼ 45.8% | -19.52M▼ 44.3% | -6.53M▲ 66.5% | -30.16M▼ 361.8% | -23.71M▲ 21.4% |
| Pretax Margin % | -582.25% | -166.57% | 6.5% | -42.62% | -56.91% | -73.68% | -34.95% | -149.16% | -139.81% |
| Income Tax | 8.46M | 0 | 0 | 0 | 27K | 78K | 185K | 61K | 169K |
| Effective Tax Rate % | -58.23% | 0% | 0% | 0% | -0.2% | -0.4% | -2.83% | -0.2% | -0.71% |
| Net Income | -22.15M▲ 0% | -1.06M▲ 95.2% | 4.96M▲ 568.8% | -9.2M▼ 285.6% | -13.55M▼ 47.4% | -19.6M▼ 44.6% | -6.72M▲ 65.7% | -30.22M▼ 350.0% | -23.88M▲ 21.0% |
| Net Margin % | -887.38% | -31.08% | 15.59% | -42.26% | -57.03% | -73.97% | -35.94% | -149.46% | -140.8% |
| Net Income Growth % | -17.28% | 95.23% | 568.78% | -285.59% | -47.36% | -44.63% | 65.73% | -350.03% | 20.99% |
| Net Income (Continuing) | -14.53M | -5.67M | 2.07M | -9.28M | -13.55M | -19.6M | -6.72M | -30.22M | -23.88M |
| Discontinued Operations | -7.62M | 4.61M | 2.89M | 80K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.64▲ 0% | -0.28▲ 95.8% | 1.26▲ 550.0% | -2.38▼ 288.9% | -3.48▼ 46.2% | -3.93▼ 12.9% | -0.75▲ 80.9% | -3.03▼ 304.0% | -2.10▲ 30.7% |
| EPS Growth % | -9.75% | 95.78% | 550% | -288.89% | -46.22% | -12.93% | 80.92% | -304% | 30.69% |
| EPS (Basic) | -6.64 | -0.28 | 1.26 | -2.38 | -3.48 | -3.93 | -0.75 | -3.03 | -2.10 |
| Diluted Shares Outstanding | 3.33M | 3.87M | 3.88M | 3.89M | 3.89M | 4.99M | 9.01M | 9.96M | 11.38M |
| Basic Shares Outstanding | 3.33M | 3.87M | 3.88M | 3.89M | 3.89M | 4.99M | 9.01M | 9.96M | 11.38M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MDWD Balance Sheet
MediWound Ltd. (MDWD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 41.52M | 32.71M | 35.62M | 26.19M | 14.95M | 45.84M | 49.7M | 52.16M | 59.96M |
| Cash & Short-Term Investments | 36.07M | 23.63M | 29.46M | 21.58M | 11.05M | 33.9M | 41.54M | 43.16M | 53.14M |
| Cash Only | 36.07M | 6.72M | 7.24M | 17.38M | 11.05M | 33.9M | 11.87M | 9.15M | 4.8M |
| Short-Term Investments | 0 | 16.92M | 22.04M | 4.02M | 0 | 0 | 29.68M | 34.01M | 48.34M |
| Accounts Receivable | 3.44M | 7.27M | 4.33M | 2.84M | 2.27M | 9.7M | 4.42M | 5.85M | 2.37M |
| Days Sales Outstanding | 502.46 | 780.01 | 49.77 | 47.63 | 34.82 | 133.56 | 86.32 | 105.63 | 51.05 |
| Inventory | 1.89M | 1.68M | 1.61M | 1.38M | 1.2M | 1.96M | 2.85M | 2.69M | 4.09M |
| Days Inventory Outstanding | 407.81 | 279.87 | 47.15 | 34.14 | 28.03 | 50.54 | 66 | 53.28 | 100.78 |
| Other Current Assets | 0 | 0 | 408K | 257K | 0 | 363K | 167K | 0 | 359K |
| Total Non-Current Assets | 2.62M | 2.56M | 4.97M | 4.88M | 4.79M | 4.18M | 16.76M | 21.33M | 26.29M |
| Property, Plant & Equipment | 1.92M | 2.02M | 4.53M | 4.51M | 4.03M | 3.58M | 15.93M | 20.8M | 25.79M |
| Fixed Asset Turnover | 1.30x | 1.68x | 7.01x | 4.82x | 5.90x | 7.40x | 1.17x | 0.97x | 0.66x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 635K | 495K | 429K | 363K | 297K | 231K | 165K | 99K | 33K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 469K | 364K | 490K | 439K | 467K |
| Other Non-Current Assets | 56K | 48K | 6K | -4.88M | -4.32M | -3.81M | 183K | 0 | 0 |
| Total Assets | 44.13M▲ 0% | 35.28M▼ 20.1% | 40.59M▲ 15.1% | 31.07M▼ 23.5% | 19.74M▼ 36.5% | 50.02M▲ 153.3% | 66.46M▲ 32.9% | 73.5M▲ 10.6% | 86.25M▲ 17.4% |
| Asset Turnover | 0.06x | 0.10x | 0.78x | 0.70x | 1.20x | 0.53x | 0.28x | 0.28x | 0.20x |
| Asset Growth % | 23.41% | -20.07% | 15.06% | -23.45% | -36.45% | 153.32% | 32.88% | 10.59% | 17.36% |
| Total Current Liabilities | 5.43M | 4.9M | 10.37M | 8.27M | 10.72M | 12.06M | 10.83M | 26.54M | 25.71M |
| Accounts Payable | 3.25M | 2.71M | 4.07M | 2.99M | 4.69M | 5.66M | 4.22M | 4.1M | 3.61M |
| Days Payables Outstanding | 702.97 | 452.29 | 118.88 | 74.02 | 109.61 | 145.63 | 97.93 | 81.07 | 88.81 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 418K | 623K |
| Deferred Revenue (Current) | 131K | 198K | 249K | 462K | 543K | 63K | 24K | 12K | 0 |
| Other Current Liabilities | 0 | 452K | 3.74M | 2.9M | 3.85M | 3.87M | 1.86M | 17.73M | 18.43M |
| Current Ratio | 7.64x | 6.68x | 3.43x | 3.17x | 1.39x | 3.80x | 4.59x | 1.97x | 2.33x |
| Quick Ratio | 7.30x | 6.34x | 3.28x | 3.00x | 1.28x | 3.64x | 4.33x | 1.86x | 2.17x |
| Cash Conversion Cycle | 207.3 | 607.59 | -21.96 | 7.75 | -46.76 | 38.47 | 54.38 | 77.84 | 63.02 |
| Total Non-Current Liabilities | 29.08M | 21.41M | 15.05M | 15.53M | 13.61M | 27.05M | 16.74M | 15.8M | 8.62M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 2.01M | 1.74M | 1.39M | 846K | 6.35M | 6.51M | 8.15M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 28.09M | 20.25M | 11.91M | 12.56M | 12.1M | 26.2M | 10.39M | 8.55M | 472K |
| Total Liabilities | 34.52M | 26.3M | 25.42M | 23.8M | 24.33M | 39.1M | 34.86M | 42.34M | 34.33M |
| Total Debt | 0 | 0 | 2.01M | 1.74M | 1.39M | 846K | 6.35M | 6.93M | 8.77M |
| Net Debt | -36.07M | -6.72M | -5.24M | -15.63M | -9.65M | -33.05M | -5.52M | -2.22M | 3.98M |
| Debt / Equity | - | - | 0.13x | 0.24x | - | 0.08x | 0.20x | 0.22x | 0.20x |
| Debt / EBITDA | - | - | 0.29x | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | -0.77x | - | - | - | - | - | - |
| Interest Coverage | - | - | 27.37x | -44.20x | -67.19x | -47.29x | -46.27x | -34.55x | -38.13x |
| Total Equity | 9.62M▲ 0% | 8.97M▼ 6.7% | 15.17M▲ 69.1% | 7.27M▼ 52.1% | -4.58M▼ 163.0% | 10.91M▲ 338.2% | 31.59M▲ 189.5% | 31.15M▼ 1.4% | 43.63M▲ 40.1% |
| Equity Growth % | 23.81% | -6.74% | 69.07% | -52.06% | -163.01% | 338.19% | 189.49% | -1.4% | 40.06% |
| Book Value per Share | 2.89 | 2.32 | 3.91 | 1.87 | -1.18 | 2.19 | 3.51 | 3.13 | 3.84 |
| Total Shareholders' Equity | 9.62M | 8.97M | 15.17M | 7.27M | -4.58M | 10.91M | 31.59M | 31.15M | 43.63M |
| Common Stock | 75K | 75K | 75K | 75K | 75K | 143K | 184K | 215K | 258K |
| Retained Earnings | -129.41M | -130.72M | -125.76M | -134.96M | -148.51M | -168.11M | -174.82M | -205.05M | -228.93M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -38K | -25K | -17K | -40K | -19K | -5K | -18K | -11K | -32K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDWD Cash Flow Statement
MediWound Ltd. (MDWD) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.45M | -12.15M | 8.29M | -6.89M | -8.92M | -11.88M | -10.46M | -13.62M | -14.53M |
| Operating CF Margin % | -659.25% | -357.37% | 26.08% | -31.68% | -37.52% | -44.86% | -56% | -67.37% | -85.68% |
| Operating CF Growth % | -0.06% | 26.14% | 168.2% | -183.18% | -29.31% | -33.3% | 11.95% | -30.19% | -6.65% |
| Net Income | -22.15M | -1.06M | 4.96M | -9.2M | -13.55M | -19.6M | -6.72M | -30.22M | -23.88M |
| Depreciation & Amortization | 567K | 577K | 1.15M | 1.09M | 1.24M | 1.27M | 1.3M | 1.48M | 1.71M |
| Stock-Based Compensation | 1.36M | 645K | 1.23M | 1.32M | 1.67M | 1.95M | 1.94M | 3.14M | 0 |
| Deferred Taxes | -1.64M | 201K | -1.86M | -373K | -124K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 7.85M | -11.51M | -1.69M | 323K | 1.69M | 11.74M | -9.33M | 10.71M | 2.87M |
| Working Capital Changes | -2.45M | -1.01M | 4.49M | -61K | 162K | -7.24M | 2.34M | 1.27M | 4.77M |
| Change in Receivables | 28K | -211K | -3.55M | 1.39M | 929K | -7.58M | 4.76M | -1.02M | 4.88M |
| Change in Inventory | -1.04M | 206K | 67K | 141K | 257K | -721K | -906K | 187K | -1.36M |
| Change in Payables | -135K | -536K | 1.35M | -1.1M | 1.72M | 414K | -594K | 406K | 2.35M |
| Cash from Investing | 437K | -17.04M | -6.9M | 17.39M | 3.55M | -481K | -34.32M | -8.4M | -19.54M |
| Capital Expenditures | -1.07M | -534K | -792K | -923K | -489K | -555K | -6.46M | -6.27M | -5.5M |
| CapEx % of Revenue | 43.07% | 15.7% | 2.49% | 4.24% | 2.06% | 2.09% | 34.59% | 31.02% | 32.46% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 349K | -16.51M | -1.05M | 274K | 35K | 74K | -27.86M | -2.12M | 0 |
| Cash from Financing | 23M | 46K | -1.01M | -629K | -1.05M | 35.76M | 22.92M | 19.39M | 29.62M |
| Debt Issued (Net) | 0 | 0 | -630K | -508K | 0 | 0 | 0 | -928K | 0 |
| Equity Issued (Net) | 1000K | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 337K | 46K | -376K | -121K | -1.05M | -2.62M | -1.99M | -1.84M | -1.43M |
| Net Change in Cash | 7.2M▲ 0% | -29.35M▼ 507.5% | 526K▲ 101.8% | 10.13M▲ 1826.6% | -6.33M▼ 162.5% | 22.85M▲ 461.0% | -22.03M▼ 196.4% | -2.71M▲ 87.7% | -4.36M▼ 60.7% |
| Free Cash Flow | -17.53M▲ 0% | -12.69M▲ 27.6% | 7.5M▲ 159.1% | -7.82M▼ 204.3% | -9.4M▼ 20.3% | -12.44M▼ 32.3% | -16.93M▼ 36.1% | -19.9M▼ 17.5% | -20.04M▼ 0.7% |
| FCF Margin % | -702.32% | -373.07% | 23.58% | -35.92% | -39.58% | -46.95% | -90.6% | -98.39% | -118.14% |
| FCF Growth % | -2.24% | 27.62% | 159.09% | -204.28% | -20.3% | -32.27% | -36.09% | -17.53% | -0.69% |
| FCF per Share | -5.26 | -3.28 | 1.93 | -2.01 | -2.42 | -2.49 | -1.88 | -2.00 | -1.76 |
| FCF Conversion (FCF/Net Income) | 0.74x | 11.50x | 1.67x | 0.75x | 0.66x | 0.61x | 1.56x | 0.45x | 0.61x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDWD Key Ratios
MediWound Ltd. (MDWD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -120.9% | -254.73% | -11.37% | 41.05% | -81.96% | -1007.51% | -619.05% | -31.6% | -96.33% | -63.86% |
| Return on Invested Capital (ROIC) | - | - | - | 69.71% | -844.59% | - | - | -589.54% | -52.85% | -49.54% |
| Gross Margin | -45.7% | 32.37% | 35.58% | 60.72% | 32.21% | 34.24% | 46.5% | 15.77% | 8.81% | 12.59% |
| Net Margin | -1212.13% | -887.38% | -31.08% | 15.59% | -42.26% | -57.03% | -73.97% | -35.94% | -149.46% | -140.8% |
| Debt / Equity | - | - | - | 0.13x | 0.24x | - | 0.08x | 0.20x | 0.22x | 0.20x |
| Interest Coverage | - | - | - | 27.37x | -44.20x | -67.19x | -47.29x | -46.27x | -34.55x | -38.13x |
| FCF Conversion | 0.87x | 0.74x | 11.50x | 1.67x | 0.75x | 0.66x | 0.61x | 1.56x | 0.45x | 0.61x |
| Revenue Growth | 159.23% | 60.21% | 36.26% | 834.7% | -31.54% | 9.19% | 11.5% | -29.48% | 8.22% | -16.14% |
MDWD Frequently Asked Questions
MediWound Ltd. (MDWD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MediWound Ltd. (MDWD) reported $17.0M in revenue for fiscal year 2025.
MediWound Ltd. (MDWD) saw revenue decline by 16.1% over the past year.
MediWound Ltd. (MDWD) reported a net loss of $23.9M for fiscal year 2025.
Dividend & Returns
MediWound Ltd. (MDWD) has a return on equity (ROE) of -63.9%. Negative ROE indicates the company is unprofitable.
MediWound Ltd. (MDWD) had negative free cash flow of $20.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More MDWD
MediWound Ltd. (MDWD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates